Project Grant R01AG084214
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$828K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This federal Project Grant award, with an ID of R01AG090773, is funded by the National Institute on Aging under the Aging Research Program (CFDA 93.866). The University of California, Los Angeles (UCLA) is the prime awardee and will receive $751,442 over the period from December 15, 2024 to November 30, 2029. The goal of this project is to optimize and evaluate a brain-penetrant CRISPR-based gene editing approach to convert the Alzheimer's disease genetic risk factor APOE4 to the benign APOE3...
This $1,848,461 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the McLaughlin Research Institute for Biomedical Sciences, Inc. will investigate the role of neutrophilic inflammation as a mediator of neuroinflammation and cognitive decline in individuals with different apolipoprotein E (APOE) genotypes. The 5-year study aims to 1) examine APOE genotype-specific differences in neutrophil activation and lifespan in the gastrointestinal tract, periphery,...
This Project Grant award of $341,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) will fund research at The Roskamp Institute, Inc., a non-profit biotechnology research organization in Sarasota, Florida. The project aims to examine the influence of different APOE genotypes (a major genetic risk factor for Alzheimer's disease) on the GLP-1R-AMPK-ACC pathway in cerebrovascular cells and astrocytes, and determine whether treatments that activate this...
This $1,559,999 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive study to elucidate how the AANCR enhancer RNA regulates APOE gene expression and how APOE function affects cellular responses to stress in the central nervous system. The research aims to advance understanding of APOE4, a major genetic risk factor for Alzheimer's disease, in order to inform the development of targeted interventions. The project will leverage...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $564,530.00 to Emory University to investigate the association between the Alzheimer's disease risk gene APOE4 and the menopause-related hormone follicle-stimulating hormone (FSH) in the initiation and progression of Alzheimer's disease, particularly in women. The research aims to explore how APOE4 may facilitate Alzheimer's pathology related to FSH-induced mechanisms, including tau...
This is a Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on characterizing microvascular impairment in adults with elevated genetic risk for Alzheimer's disease. The $831,583 grant, awarded on March 15, 2025, will fund a comprehensive study to elucidate the physiological mechanisms through which the APOE-E4 gene contributes to microvascular...
This Project Grant award of $705,775 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive study of mitochondrial diversity in the aging brain and immune system. The primary objectives are to: Generate high-resolution mitochondrial gene expression profiles ("mitotypes") for over 1.4 million brain cells and 0.9 million immune cells from older adults to identify mitochondrial recalibrations associated with age, sex, cognitive reserve, and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,067,449 to the Icahn School of Medicine at Mount Sinai to investigate the interactive effects of the Alzheimer's disease genetic risk factor APOE4 and ketogenic diets on Alzheimer's disease pathogenesis. The 5-year research project aims to utilize in vitro brain tissue models and APOE-humanized mice to uncover the underlying mechanisms by which APOE4 genotype and high-fat/ketogenic...